The Company has informed the Exchange regarding receipt of final approval by our Subsidiary, Caplin Steriles Limited, from the USFDA for the ANDA Methylprednisolone Acetate Injectable Suspension USP.
CAPLIPOINT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Caplin Point Laboratories' subsidiary Caplin Steriles Limited has received final approval from the US health regulator (USFDA) for its generic injectable product Methylprednisolone Acetate Injectable Suspension USP. This approval allows the subsidiary to manufacture and market this product in the US market. Methylprednisolone is a widely used corticosteroid for treating inflammation, severe allergies, and autoimmune conditions. The approval adds to Caplin Steriles' growing US product portfolio of injectable generics. Methylprednisolone acetate injections have strong existing demand in the US market, and this approval opens a new revenue opportunity through the US distribution channel.
This is a positive development for shareholders as USFDA approvals typically translate into new revenue streams from the lucrative US generics market, supporting future growth of the subsidiary and the consolidated business.